Skip to main content
. Author manuscript; available in PMC: 2016 Apr 4.
Published in final edited form as: Clin Cancer Res. 2012 Mar 8;18(8):2130–2132. doi: 10.1158/1078-0432.CCR-12-0454

Figure 1.

Figure 1

The fraction of agents selected for Phase III study which are effective as a function of the % of active agents undergoing Phase II testing, the false positive rate (fp) and the true positive rate (tp) of the design.

The properties fp and tp depend on the chosen Phase II design and how the Phase II endpoint and Phase III endpoint models jointly depend on the treatment assignment for the specific disease.